NR4A1 and breast carcinoma: Although there is currently no known physiological ligand for Nur77, a number of small molecules, including CsnB [37] and bis-indole-derived compounds [40], have been identified as Nur77 agonists and have been shown to have antitumor effects on gastric, colorectal, and breast cancer.